In addressing this imperative, extracellular vesicles (EVs) have emerged as a cutting-edge solution in the realm of targeted drug delivery. These nanoscale, membrane-enclosed particles are naturally secreted by virtually all cell types and possess unique biological properties that make them highly attractive for therapeutic applications. EVs are inherently biocompatible and non-immunogenic, enabling them to circulate in the bloodstream without eliciting adverse immune responses. Moreover, their capacity to traverse biological barriers and bypass lysosomal degradation pathways permits efficient cytosolic delivery of payloads, making them superior to many synthetic carriers in terms of intracellular drug transport.

Capitalizing on these attributes, a research team led by Dr. Ramesh at the University of Oklahoma has pioneered a sophisticated EV-based platform specifically engineered for lung cancer therapy. This platform ingeniously integrates nanotechnology with biochemical targeting strategies and controlled drug release mechanisms to create a multifunctional therapeutic vector. Central to their design is the surface modification of EVs with transferrin (Tf), a protein that selectively binds to the transferrin receptor (TfR), which is markedly overexpressed on the surface of lung cancer cells. This targeted approach significantly enhances the selective uptake of the drug-loaded EVs by tumor cells, thus amplifying therapeutic efficacy.

The therapeutic payload encapsulated within these engineered EVs consists of gold nanoparticle (GNP)-cisplatin conjugates, a conjugate that merges the potent cytotoxicity of cisplatin with the versatile photothermal properties of gold nanoparticles. This innovative combination ensures a pH-responsive release of cisplatin; the acidic microenvironment characteristic of tumor sites triggers the accelerated release of the drug, thereby providing spatially and temporally controlled chemotherapy. The strategic design maximizes the cytotoxic impact on malignant cells while minimizing collateral damage to healthy lung tissue and other organs, such as the kidneys, where cisplatin-induced nephrotoxicity is a significant clinical concern.

Extensive in vitro studies demonstrated that these tumor-targeted multifunctional extracellular vesicles (tt-Mfn-EVs) exhibit enhanced cellular internalization and intracellular drug delivery specifically in TfR-overexpressing lung cancer cells. This selective cytotoxicity was corroborated by increased markers of apoptosis and DNA damage within the treated cancer cells. Importantly, the platform displayed minimal toxicity toward normal human lung and kidney cells, underscoring the potential of this delivery system to reduce systemic side effects compared to conventional chemotherapy regimens.

Beyond their chemotherapeutic capabilities, the GNP-loaded EVs possess intrinsic photothermal properties, enabling their use in combined photothermal and chemotherapy treatments. Upon near-infrared irradiation, the gold nanoparticles convert light energy into heat, causing localized hyperthermia that further sensitizes tumor cells to chemotherapeutic agents. This combinatorial strategy not only intensifies tumor cell eradication but also expands the therapeutic versatility of the platform, opening avenues for multimodal cancer treatments that can be tailored to individual patient needs.

This multifunctional EV platform marks a significant departure from traditional passive drug carriers by functioning as an active, tumor-targeted system that responds dynamically to the tumor microenvironment. The incorporation of pH-responsive drug release and receptor-mediated cellular uptake mechanisms exemplifies a precision medicine approach, designed to maximize therapeutic benefit while mitigating the risk of off-target toxicities. The ability to fine-tune drug release kinetics and employ external stimuli such as photothermal activation positions this platform at the forefront of next-generation nano-bio therapeutics.

The implications of this research transcend lung cancer, as the modular nature of the EV platform allows for adaptation to various cancer types and potentially other diseases characterized by aberrant receptor expression or distinct microenvironmental features. Moreover, the biocompatibility and intrinsic targeting capabilities of EVs make them well-suited for theranostic applications, combining therapeutic and diagnostic functions into a single nanoscale vector. This convergence could revolutionize current patient monitoring paradigms by enabling real-time tracking of drug delivery and therapeutic response.

Published in the journal Extracellular Vesicles and Circulating Nucleic Acids, the study titled “Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy” provides a comprehensive blueprint for harnessing the synergistic potential of EV biology and nanotechnology. The paper meticulously details the synthesis of GNP-cisplatin conjugates, EV isolation and surface functionalization protocols, and in vitro efficacy assessments, furnishing a robust foundation for future preclinical and clinical investigations.

As the oncology field moves toward personalized medicine, the ability to deploy such sophisticated, responsive drug delivery systems augurs well for enhancing patient outcomes. The study’s demonstration of minimized nephrotoxicity and systemic side effects highlights a critical advance in chemotherapeutic precision, addressing long-standing clinical challenges associated with cisplatin-based regimens. The integration of nanotechnology and biological delivery vehicles represents a promising frontier that could reshape cancer therapeutics in the coming decades.

In summary, the research by Dr. Ramesh and colleagues epitomizes the potential of extracellular vesicle-based nanomedicine to provide targeted, efficient, and safer cancer therapies. By engineering multifunctional EVs capable of selective tumor targeting, environment-responsive drug release, and adjunct photothermal therapy, this platform stands poised to offer a transformative impact on lung cancer treatment and beyond. Continued advancements and clinical translation of such technologies will be pivotal in realizing the promise of precision oncology.

Subject of Research: Not applicable
Article Title: Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy
News Publication Date: 23-Dec-2025
Web References: http://dx.doi.org/10.20517/evcna.2025.39
References: Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy, Extracellular Vesicles and Circulating Nucleic Acids, Dec. 23, 2025
Image Credits: HIGHER EDUCATION PRESS
Keywords: Cell biology

At the heart of these DNA-based microbots is a sophisticated biochemical programmability. Each flower’s DNA is encoded with structural information that functions like a molecular computer program, orchestrating precise movements and reactions to external changes. When the surrounding biochemical environment shifts, particularly with fluctuations in acidity or pH, the DNA components respond by contracting or relaxing. This dynamic folding mechanism enables the flowers to open, close, or excrete chemical agents, mimicking the nuanced responses of living biological systems and paving the way for autonomous microscopic machines capable of complex tasks.

Dr. Ronit Freeman, the principal investigator and director of the Freeman Lab at UNC, highlights the transformative potential of this technology for medicine and beyond. She envisions applications such as ingestible or implantable capsules that use shape-shifting DNA flowers to deliver targeted therapeutics precisely when and where they are needed. The ability to activate medication upon detecting disease markers and cease function upon healing heralds a future where treatment is not only programmable but also intrinsically responsive, minimizing side effects and enhancing efficacy in ways conventional drug delivery methods simply cannot match.

The conceptual inspiration for this innovation stems from observing natural phenomena—how flowers unfurl their petals at dawn, coral polyps pulsate rhythmically, and tissues morph and grow in organisms. These biological processes involve complex, hierarchical self-assembly and responsiveness, which scientists have long attempted to replicate at micro and nanoscale. Capturing this complexity in synthetic materials has been a significant challenge due to limitations in material adaptability and responsiveness. However, the UNC team’s DNA-inorganic hybrid crystal platform ingeniously emulates these natural processes, integrating molecular recognition and mechanical actuation seamlessly.

The key to the flower’s metamorphosis lies in the precise arrangement and hierarchical structuring of the DNA within the crystal lattice. Under acidic conditions, which commonly characterize pathological environments such as tumors or inflamed tissues, certain DNA motifs fold tightly, resulting in the physical closure of the flower petals. This mechanical actuation is reversible; when the pH normalizes, the DNA unfolds, and the flower reopens. Such reversible conformational changes afford a programmable control mechanism that can modulate chemical reactions, cargo release, and even selective interaction with biological cells and tissues, thus functioning both as sensor and actuator at the nanoscale.

This reversible behavior is not only rapid but can be engineered with high specificity by designing DNA sequences responsive to desired chemical or physical triggers. The precise kinetic control over this folding and unfolding process means the DNA flowers can perform complex tasks autonomously without external intervention, a feature critical for practical deployment in biomedical or environmental settings. For instance, in a tumor microenvironment, the acidity-triggered closure could be exploited to release a payload of anticancer drugs directly at the tumor site while sparing healthy tissue, significantly reducing systemic toxicity.

The implications of these DNA flowers extend well beyond targeted drug delivery. In environmental science, these shape-responsive materials could revolutionize remediation strategies by releasing cleaning agents at polluted sites and subsequently breaking down harmlessly to avoid ecological impact. The ability of the DNA-inorganic framework to store and process molecular information also suggests applications in ultra-high-density data storage, where DNA’s innate information density could be harnessed to encode petabytes of data within minuscule volumes. These multifaceted utilities position DNA flowers as a versatile technological platform bridging living biological systems with engineered nanomachines.

From a materials science perspective, this research marks a paradigm shift in the design of metamaterials—engineered structures that derive unique properties from their organization rather than composition alone. The hierarchical assembly of DNA and inorganic crystals imparts not only mechanical flexibility but also biochemical reactivity, a combination rarely found in synthetic materials. This blend of properties enables the DNA flowers to operate at the interface between chemistry, biology, and robotics, effectively functioning as living materials capable of sensing, responding, and adapting autonomously in real time.

Despite being in early developmental stages, this technology demonstrates a profound leap towards realizing dynamic, shape-shifting materials inspired by natural morphogenesis. The rapid and reversible metamorphosis of these DNA-inorganic hybrids introduces new design principles for creating responsive nanostructures with programmable lifecycles and functions. Such materials may one day think, move, and adapt much like biological organisms, heralding an era where synthetic systems possess lifelike autonomy for applications spanning medicine, environmental management, and information technology.

Looking forward, the versatility of DNA-based structural programming and the possibility of integrating additional molecular components offer exciting prospects for creating even more multifunctional soft robots. By tuning the DNA sequences, inorganic composition, and environmental triggers, researchers could tailor the flowers to respond to a wider range of biological signals or perform multifaceted tasks, such as simultaneous sensing and delivery, environmental monitoring coupled with remediation, or dynamic interaction with living cells for regenerative medicine. This modular approach underlines a new frontier in material science where form and function are dictated by programmable molecular architecture.

In summary, UNC’s pioneering “DNA flower” soft robots exemplify an innovative leap in nanotechnology, combining molecular programming with structural metamorphosis to produce materials that not only mimic but also extend the capabilities of biological systems. These microscopic robots hold promise for transforming how medicine is delivered, environmental pollutants are treated, and data is stored, bringing science fiction’s vision of autonomous, intelligent materials closer to reality. As research progresses, these DNA-inorganic crystals could be foundational in developing the next generation of smart materials that seamlessly integrate sensing, actuation, and computation at the nanoscale.

Subject of Research: DNA-based microscopic soft robots with reversible shape-shifting capabilities

Article Title: Reversible Metamorphosis of Hierarchical DNA-Inorganic Crystals

News Publication Date: 20-Oct-2025

Web References: https://www.nature.com/articles/s41565-025-02026-8

References: DOI 10.1038/s41565-025-02026-8

Image Credits: Justin Hill, Philip Rosenberg, and Ronit Freeman

Keywords: Robotics, DNA, Biomimetics, Soft robotics

At the core of this breakthrough lies the design and synthesis of specialized nanoparticles that serve as vehicles for messenger RNA (mRNA) and gene-editing tools. Over 150 distinct material variants were synthesized and rigorously tested in preclinical models, leading to the identification of a novel class of ionizable lipopolymers optimized for pulmonary delivery. These nanocarriers efficiently encapsulate genetic payloads, ensuring their stability during transit and enabling targeted uptake by lung cells. Such precise targeting is paramount to maximizing therapeutic efficacy while minimizing off-target effects.

The team employed a sophisticated chemical strategy utilizing the split-Ugi reaction—a modular and streamlined synthetic approach—to rapidly generate a diverse library of lung-specific lipids. These custom molecules self-assemble into nanocarriers that navigate the complex lung microenvironment, overcoming biological barriers such as mucus and immune clearance. This approach not only facilitates delivery of nucleic acids of varying sizes but also provides a versatile platform adaptable for delivering a spectrum of genetic medicines to different organs.

Insights gleaned from rigorous in vivo studies using murine models demonstrated that these nanoparticle formulations not only localize genetic materials effectively within lung tissue but also exhibit a favorable safety profile. In models of lung cancer, administration of mRNA and gene-editing agents via these nanocarriers significantly attenuated tumor progression. Concurrently, in cystic fibrosis models—a disease caused by mutations in a single gene disrupting lung function—the therapy restored pulmonary performance by correcting underlying genetic defects, underscoring the translational potential.

The implications of this work extend beyond the immediate therapeutic targets. By enabling targeted activation of the immune system against malignant cells and simultaneously restoring normal function in genetic lung diseases, the technology exemplifies the dual power of next-generation genetic medicines. The elimination of harmful side effects traditionally associated with systemic therapies highlights the advanced specificity and controlled delivery inherent in this nanoparticle platform.

Central to these advances is the synthesis method itself, which accelerates the development cycle of lung-targeted therapies. The split-Ugi reaction facilitates rapid and scalable production of ionizable lipopolymers, granting researchers the agility to fine-tune lipid structures for optimal interaction with lung tissue and intracellular machinery. This synthetic flexibility empowers the rational design of nanocarriers tailored to address a broad spectrum of pulmonary disorders.

The research was published across two prominent journals, including Nature Communications and the Journal of the American Chemical Society, reflecting the interdisciplinary nature and high impact of this work. Key contributors from Oregon State University’s College of Pharmacy, led by Gaurav Sahay, coordinated efforts spanning medicinal chemistry, molecular biology, and pulmonary medicine to realize this ambitious vision.

Importantly, this novel delivery system circumvents challenges that have long impeded progress in pulmonary gene therapy, such as degradation of nucleic acids, inefficient cellular uptake, and immune rejection. By precisely engineering the physical and chemical properties of the nanocarriers, the team achieved a delicate balance—preserving the integrity of genetic cargo while promoting effective internalization by target lung cells.

The long-term goal articulated by the researchers centers on establishing a robust, adaptable platform capable of delivering diverse genetic therapies with maximal precision and minimal collateral effects. This foundational technology paves the way toward personalized respiratory medicine, where treatments can be custom-designed for specific genetic mutations or cancer subtypes, potentially revolutionizing standards of care for fatal and chronic lung diseases.

Funding and support for this research were provided by prominent institutions including the Cystic Fibrosis Foundation, the National Cancer Institute, and the National Heart, Lung, and Blood Institute, underscoring the clinical significance and urgent need for novel pulmonary therapeutics. Moreover, the team’s proactive steps toward translating this innovation are evident in the filing of provisional patents and active collaboration with biotech enterprises, bridging the gap from bench to bedside.

This landmark study heralds a new chapter in respiratory medicine, where nanotechnology converges with genetic engineering to unlock potent, disease-modifying interventions. The fusion of synthetic chemistry, targeted delivery, and genetic medicine showcased in this work sets a precedent for future therapies that could dramatically improve outcomes for millions suffering from lung ailments worldwide.

As the scientific community continues to unravel the complexities of lung biology and genetic disease, such cutting-edge platforms will be instrumental in overcoming previous therapeutic limitations. By refining and extending these approaches, researchers envisage expanding applications beyond lung cancer and cystic fibrosis to a wider spectrum of pulmonary and systemic diseases with genetic underpinnings.

In summary, the Oregon State-led team’s success in engineering ionizable lipopolymer nanoparticles through a strategic synthetic route marks a pivotal advancement in nanomedicine and gene therapy. By harnessing the power of targeted delivery and genetic precision, this technology lays the groundwork for safer, more efficient treatments that directly confront the root causes of respiratory illnesses—a breakthrough poised to reshape the future of medicine.

Subject of Research: Animals

Article Title: Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing

News Publication Date: 29-Apr-2025

Web References:

• https://www.nature.com/articles/s41467-025-59136-z
• https://pubs.acs.org/doi/10.1021/jacs.5c04123

Image Credits: Scientists have made a key breakthrough for treating respiratory diseases by developing a new drug delivery system that transports genetic therapies directly to the lungs, opening promising possibilities for patients with conditions like lung cancer and cystic fibrosis. Illustration provided by Gaurav Sahay, OSU College of Pharmacy.

Keywords: Nanoparticles, Pulmonary Delivery, Gene Therapy, Messenger RNA, Lung Cancer, Cystic Fibrosis, Ionizable Lipopolymers, Split-Ugi Reaction, Genetic Medicine, Targeted Drug Delivery, Nanomedicine, Respiratory Disease

The research team, led by Professor Makiya Nishikawa, explored the use of DNA as a foundational material for hydrogels due to its inherent customizable physicochemical characteristics. Hydrogels themselves are polymeric substances characterized by their capacity to maintain large volumes of water while housed within a three-dimensional network. As drug carriers, they offer an effective means of encapsulating various bioactive agents, thus supporting prolonged release profiles that are essential for therapeutic effectiveness. However, traditional methodologies utilizing DNA ligase present significant limitations, including the potential for allergic reactions and complex administration protocols.

To surmount these challenges, the team designed a novel polypod-like nanostructure, termed a polypodna, comprised of a minimal number of oligodeoxynucleotides (ODNs) with partially complementary sequences. These sophisticated arrangements facilitate the creation of hydrogels that can easily reform at the site of injection, negating the need for cumbersome DNA ligase processes. While innovative, prior models necessitated a high number of ODNs, leading to increased costs, complexity, and risk of off-target effects as the base-pairing complexities multiplied.

In a revolutionary pivot, the researchers introduced a Takumi-shaped DNA unit, reducing the requisite number of ODNs to just two. Their goal was to optimize and miniaturize these DNA nanostructures to assemble hydrogels effectively while addressing issues such as stability and retention time. The motivation stemmed from the desire to craft an efficient drug delivery system without compromising the integrity of the gel and thereby enhancing its potential for clinical applications.

The Takumi-shaped DNA structure was constructed using eight to eighteen nucleotide-long palindromic stems, attached to two cohesive components flanking each side via a thymidine spacer. Each ODN was precisely categorized based on its unique length parameters, allowing for an in-depth analysis of structural performance concerning hydrogel functionality. Notably, this provided clarity on how variations in stem and cohesive part lengths influenced melting temperatures, stability, and, ultimately, the formation of the hydrogel.

Through their rigorous experimentation, the team uncovered that ODNs with stem lengths of twelve nucleotides or longer were crucial for effective hydrogel formation, establishing a baseline for future studies. Equally important, they discovered that cohesive parts exhibited optimal behavior at ten nucleotides in length, resulting in enhanced hybridization properties and significantly better thermal stability across the spectrum of tested hydrogel configurations.

Their studies not only demonstrated the feasibility of using minimal DNA units for hydrogel creation but also provided insights into the mechanical properties of these gels. The fluctuation of storage modulus—indicative of how the hydrogel responds under various physical conditions—was evaluated by adjusting the lengths of cohesive parts. Their findings indicated that GC-rich cohesive parts of ten nucleotides were far superior concerning thermal stability compared to their counterparts. Such insights are invaluable for future endeavors in designing optimized delivery systems capable of precise therapeutic interventions.

The implications of these findings were thoroughly validated through in vivo experiments. Introducing doxorubicin-intercalated DNA hydrogels derived from the 12s-(T-10c)₂-ODNs into mouse models revealed a remarkable retention period exceeding 168 hours post-administration. This protracted presence significantly correlated with enhanced anti-tumor efficacy attributed to controlled drug release, showcasing the hydrogels’ potential as an influential player in oncological therapeutics.

Following a sustained subcutaneous injection of the enhanced hydrogels, Professor Nishikawa noted, “The optimized DNA hydrogel prepared using 12s-(T-10c)₂ exhibited a more sustained retention than the hexapodna-based DNA hydrogel after in vivo administration in mice.” This pivotal observation not only underscores the efficiency of the new design but also highlights its potential utility in targeted immune responses, positioning Takumi-shaped DNA hydrogels as effective antigen delivery systems.

Beyond their application in oncology, the findings of this study pave the way for versatile biomedical applications by harnessing the inherent advantages of DNA in creating biomaterials that are both biocompatible and effective. With minimal DNA unit assembly serving as the crux of this innovation, the study meets the pressing demand for advanced delivery systems in an evolving biomedical landscape, reinforcing the significant potential of DNA-based hydrogels in therapeutic strategies.

Overall, the research team’s endeavor not only contributes new knowledge to the field of drug delivery but also represents a notable step towards creating innovative, patient-centered therapies that prioritize efficiency and ease of administration. This forward-thinking approach to drug delivery and material science epitomizes the shifting paradigms in medicine where precision is pivotal and streamlined processes can greatly enhance patient outcomes.

With a profound impact on the future of pharmacology and therapeutic delivery methods, the authors invite further exploration and support from the scientific community to refine and expand upon these promising techniques. The successful transition from laboratory research to real-world clinical applications remains an ongoing journey, yet this study serves as a formidable foundation upon which future innovations in drug delivery systems can be built.

In conclusion, the collaborative efforts of the research team at the Tokyo University of Science mark a pivotal moment in biomedical engineering. By effectively utilizing the properties of DNA to craft hydrogels, they advance the field towards smarter, safer, and highly effective drug delivery solutions that have the potential to transform patient care at a fundamental level.

Subject of Research: DNA-based hydrogels for drug delivery systems
Article Title: Biocompatible DNA hydrogel composed of minimized Takumi-shaped DNA nanostructure exhibits sustained retention after in vivo administration
News Publication Date: 10-Jan-2025
Web References:
References:
Image Credits: Prof. Makiya Nishikawa, Tokyo University of Science

Keywords: DNA hydrogels, drug delivery, biocompatibility, sustained release, pharmacology, targeted therapies, nanostructures, biopharmaceuticals, gene therapy, biomedical engineering, polymer chemistry, in vivo experiments.